Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario.
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population / Casadei-Gardini, A., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Rimassa, L., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Kumada, T., Sakamoto, N., Iwamoto, H., Aoki, T., Chon, H.J., et al.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 180:(2023), pp. 9-20. [10.1016/j.ejca.2022.11.017]
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
Casadei-Gardini, Andrea
Primo
;Rimini, MargheritaSecondo
;Della Corte, Angelo;Ratti, Francesca;De Cobelli, Francesco;Aldrighetti, Luca;Cascinu, StefanoPenultimo
;
2023-01-01
Abstract
Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario.| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0959804922017622.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
1.06 MB
Formato
Adobe PDF
|
1.06 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


